Related references
Note: Only part of the references are listed.Variants and new entities of bladder cancer
Antonio Lopez-Beltran et al.
HISTOPATHOLOGY (2019)
Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy
Wen Cheng et al.
ONCOGENESIS (2018)
Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond
Jason Zhu et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan et al.
NATURE (2018)
Presence of lymphocytic infiltrate cytotoxic T lymphocyte CD3+, CD8+, and immunoscore as prognostic marker in patients after radical cystectomy
Alice Yu et al.
PLOS ONE (2018)
Molecular Subtypes of Bladder Cancer
David J. McConkey et al.
CURRENT ONCOLOGY REPORTS (2018)
Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions
Abhishek Tripathi et al.
CURRENT UROLOGY REPORTS (2018)
Building on a Solid Foundation: Enhancing Bacillus Calmette-Guerin Therapy
Cyrill A. Rentsch et al.
EUROPEAN UROLOGY FOCUS (2018)
Low Frequency of Intratumor Heterogeneity in Bladder Cancer Tissue Microarrays
Lovisa Jakobsson et al.
BLADDER CANCER (2018)
A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157
Noah M. Hahn et al.
CLINICAL CANCER RESEARCH (2017)
Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study
Roisin M. Connolly et al.
CLINICAL CANCER RESEARCH (2017)
Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification
Gottfrid Sjodahl et al.
JOURNAL OF PATHOLOGY (2017)
FOXA1 and CK14 as markers of luminal and basal subtypes in histologic variants of bladder cancer and their associated conventional urothelial carcinoma
Joshua I. Warrick et al.
VIRCHOWS ARCHIV (2017)
Biomarkers for immunotherapy in bladder cancer: a moving target
David H. Aggen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future Perspectives
Steven A. Mann et al.
CURRENT DRUG METABOLISM (2017)
Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer
Michael J. Topper et al.
CELL (2017)
Assessing PDL-1 and PD-1 in NoneSmall Cell Lung Cancer: A Novel Immunoscore Approach
Erna-Elise Paulsen et al.
CLINICAL LUNG CANCER (2017)
Squamous Dysplasia of the Urinary Bladder: A Consecutive Cystectomy Series
Joshua I. Warrick et al.
INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY (2016)
Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement
Matthew I. Milowsky et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
Christophe Massard et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Jonathan E. Rosenberg et al.
LANCET (2016)
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
Geoffrey T. Gibney et al.
LANCET ONCOLOGY (2016)
Loss of FOXA1 Drives Sexually Dimorphic Changes in Urothelial Differentiation and Is an Independent Predictor of Poor Prognosis in Bladder Cancer
Opal L. Reddy et al.
AMERICAN JOURNAL OF PATHOLOGY (2015)
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
Katherine B. Chiappinelli et al.
CELL (2015)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up
J. Bellmunt et al.
ANNALS OF ONCOLOGY (2014)
Comprehensive molecular characterization of urothelial bladder carcinoma
John N. Weinstein et al.
NATURE (2014)
Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology
Jeffrey S. Damrauer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Infiltration of CD3+ and CD68+ cells in bladder cancer is subtype specific and affects the outcome of patients with muscle-invasive tumors
Gottfrid Sjodahl et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2014)
Adaptive resistance: A tumor strategy to evade immune attack
Sheng Yao et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2013)
A Molecular Taxonomy for Urothelial Carcinoma
Gottfrid Sjodahl et al.
CLINICAL CANCER RESEARCH (2012)
Cancer classification using the Immunoscore: a worldwide task force
Jerome Galon et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Three differentiation states risk-stratify bladder cancer into distinct subtypes
Jens-Peter Volkmer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Inactivation of p53 and Pten promotes invasive bladder cancer
Anna M. Puzio-Kuter et al.
GENES & DEVELOPMENT (2009)
The immunobiology of cancer immunosurveillance and immunoediting
GP Dunn et al.
IMMUNITY (2004)
Share Paper
